BRD9 Degrader Compounds for BAF-Related Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BAF complex-related disorders, such as cancer and infections, lack effective agents that can reduce the levels and/or activity of BRD9, a component of the BAF complex, which is upregulated in multiple cancer cell lines and involved in cellular antiviral activities.
Innovation Solution
Development of compounds with a BRD9 binding moiety and a degradation moiety linked by various linkers to target and degrade BRD9, thereby reducing its levels and activity in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for BAF complex-related disorders, then current standard care is maintained, but effective reduction of BRD9 levels and activity is not achieved
Solution Approach 1:
The patent extracts and targets BRD9 specifically from the BAF complex through degrader compounds that selectively bind to and degrade BRD9, separating its harmful effects from the rest of the complex while maintaining potential beneficial functions of other BAF components
Solution Approach 2:
The patent changes the parameter of BRD9 levels and activity by introducing compounds that modify BRD9 stability and degradation rates, thereby reducing BRD9 protein levels and associated harmful activities in cancer and infection models
2Reliability
If BRD9 is depleted in cells, then treatment of BAF-related disorders is improved, but cellular antiviral activities may be affected
Solution Approach 1:
The patent applies local quality by selectively targeting BRD9 for degradation while attempting to preserve other components of the BAF complex and their antiviral functions, creating a localized effect that reduces BRD9-driven pathology without globally impacting cellular antiviral capabilities
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring of BRD9 levels, BAF complex composition, and antiviral activity to adjust degradation intensity and duration, preventing excessive depletion that would compromise protective antiviral functions
Data Source
AI summary
The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.